| Medication | Ratioa |
|---|---|
| Testosterone | ~1:1 |
| Androstanolone (DHT) | ~1:1 |
| Methyltestosterone | ~1:1 |
| Methandriol | ~1:1 |
| Fluoxymesterone | 1:1–1:15 |
| Metandienone | 1:1–1:8 |
| Drostanolone | 1:3–1:4 |
| Metenolone | 1:2–1:30 |
| Oxymetholone | 1:2–1:9 |
| Oxandrolone | 1:3–1:13 |
| Stanozolol | 1:1–1:30 |
| Nandrolone | 1:3–1:16 |
| Ethylestrenol | 1:2–1:19 |
| Norethandrolone | 1:1–1:20 |
| Notes: In rodents. Footnotes: a = Ratio of androgenic to anabolic activity. Sources: [1]: 735 [2][3][4] | |
Template documentationReferences
- ^ Katzung BG, Chrousos GP, eds. (2012). "The Gonadal Hormones & Inhibitors". Basic & Clinical Pharmacology. New York London: McGraw-Hill Medical McGraw-Hill distributor. p. 735. ISBN 0071764011.
- ^ Potts GO, Arnold A, Beyler AL (1976). "Dissociation of the Androgenic and Other Hormonal Activities from the Protein Anabolic Effects of Steroids". In Kochakian CD (ed.). Anabolic-Androgenic Steroids. Handbook of Experimental Pharmacology. Vol. 43. pp. 361–406. doi:10.1007/978-3-642-66353-6_11.
- ^ Mozayani A, Raymon L (15 October 2003). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 504–. ISBN 978-1-59259-654-6.
- ^ Camerino B, Sala G (1960). "Anabolic Steroids". Progress in Drug Research. pp. 71–134. doi:10.1007/978-3-0348-7038-2_2.